Pillar: The Moment Category: Educational / What Is Reading time: 11 min Target keywords: what is GLP-1, GLP-1 hormone, glucagon-like peptide 1, GLP-1 explained, natural GLP-1 Meta description: GLP-1 (glucagon-like peptide-1) is a hormone produced in your intestine that regulates appetite, blood sugar, and metabolic signaling. Here's what it is, how it works, and what the research says about supporting it naturally.
Quick Answer: GLP-1 (glucagon-like peptide-1) is a hormone produced by specialized cells in your intestine in response to food. It signals satiety to the brain, slows gastric emptying, stimulates insulin release, and modulates blood glucose. GLP-1 receptor agonist drugs like semaglutide (Ozempic, Wegovy) mimic this hormone pharmacologically. The gut microbiome and certain dietary compounds also influence the body's own GLP-1 production.
In 2023, GLP-1 agonist drugs became the most-prescribed weight loss medications in history. Millions of people suddenly became very interested in a hormone most had never heard of.
The interest is warranted. GLP-1 is not a pharmaceutical invention — it's a hormone your body has been producing your entire life. The drugs work because they mimic it. Understanding the hormone itself tells you something important about how human metabolism actually works — and what happens when it doesn't.
What GLP-1 Is
Glucagon-like peptide-1 (GLP-1) is an incretin hormone — a class of gut-derived hormones that stimulate insulin secretion in response to food intake. It is produced and secreted by enteroendocrine L-cells, specialized cells found throughout the small intestine and colon that are activated when nutrients (particularly carbohydrates and fats) arrive from the stomach.
The "glucagon-like" in the name refers to its structural similarity to glucagon, a counter-regulatory hormone. But GLP-1's effects are largely opposite: where glucagon raises blood glucose, GLP-1 coordinates the processes that lower and stabilize it.
GLP-1 was first characterized in the late 1970s and early 1980s, with the landmark studies by Mihail Mojsov and Joel Habener at Harvard identifying its structure and insulinotropic function. The discovery that GLP-1 could stimulate insulin release in a glucose-dependent manner — meaning it only triggers insulin when blood glucose is elevated, not when it's already normal — made it immediately interesting as a target for type 2 diabetes treatment.
What GLP-1 Does in the Body
GLP-1 is a multi-system hormone. Its effects extend well beyond insulin regulation:
1. Insulin Secretion
GLP-1 binds to GLP-1 receptors (GLP-1R) on pancreatic beta cells, stimulating insulin release in proportion to the rise in blood glucose following a meal. This "glucose-dependent" action is what makes GLP-1-based therapies safer than earlier diabetes drugs that caused hypoglycemia regardless of glucose levels.
2. Glucagon Suppression
GLP-1 simultaneously suppresses glucagon secretion from pancreatic alpha cells. Glucagon's primary function is to raise blood glucose by stimulating liver glycogen breakdown. By suppressing glucagon post-meal, GLP-1 prevents inappropriate glucose production while the body is already processing a meal.
3. Gastric Emptying
GLP-1 slows the rate at which the stomach empties food into the small intestine. This slower transit rate reduces the speed at which glucose enters the bloodstream, blunting post-meal glucose spikes and extending the satiety signal.
4. Satiety and Appetite
GLP-1 receptors are expressed throughout the brain, including the hypothalamus and brainstem regions that regulate hunger and satiety. When GLP-1 binds these receptors — either directly or via the vagus nerve — it reduces appetite and promotes feelings of fullness. This central effect is the primary mechanism by which GLP-1 agonist drugs produce weight loss.
5. Cardiovascular Effects
GLP-1 receptors are expressed in the heart and blood vessels. Multiple large cardiovascular outcomes trials have demonstrated that GLP-1 receptor agonist drugs reduce the risk of major cardiovascular events in people with type 2 diabetes and cardiovascular disease — an effect now believed to involve direct GLP-1R signaling in cardiac tissue, independent of glucose lowering.
GLP-1 and the Gut Microbiome
One of the most significant recent findings in GLP-1 research is the extent to which gut bacteria influence GLP-1 production.
L-cells — the intestinal cells that secrete GLP-1 — respond to both direct nutrient contact and to bacterial metabolites produced in the colon. Two primary pathways have been identified:
Short-chain fatty acids (SCFAs): When gut bacteria ferment dietary fiber, they produce short-chain fatty acids including butyrate, propionate, and acetate. These SCFAs bind to free fatty acid receptors (FFAR2 and FFAR3) on L-cells, directly stimulating GLP-1 secretion. A landmark 2012 study published in Diabetes (Tolhurst et al.) established this pathway in human intestinal tissue.
Akkermansia muciniphila: This bacterium, which colonizes the mucus layer of the intestinal wall, produces a surface protein called P9 that has been shown to stimulate GLP-1 secretion through ICAM-2 receptor binding and subsequent calcium signaling in enteroendocrine cells. A 2021 study published in Nature Metabolism (Plovier et al.) documented this mechanism in detail. Akkermansia abundance is consistently lower in populations with obesity and metabolic syndrome than in those with healthy metabolic function.
Bile acid signaling: Bile acids, whose metabolism in the colon is largely controlled by gut bacteria, also stimulate GLP-1 release through TGR5 receptor activation on L-cells.
The practical implication: the gut microbiome is a meaningful determinant of GLP-1 production. Microbiome dysbiosis — imbalance or reduced diversity — can impair the bacterial signals that drive GLP-1 secretion, independent of diet.
How GLP-1 Receptor Agonist Drugs Work
GLP-1 receptor agonist drugs (GLP-1RAs) mimic the action of endogenous GLP-1 by binding to the same GLP-1 receptor — but with important differences:
Half-life: Endogenous GLP-1 has a half-life of approximately 2 minutes, rapidly degraded by the enzyme dipeptidyl peptidase-4 (DPP-4). GLP-1RA drugs are engineered to resist DPP-4 degradation, dramatically extending their activity. Semaglutide (Ozempic, Wegovy) has a half-life of approximately 7 days, allowing once-weekly dosing.
Plasma concentration: GLP-1RA drugs achieve far higher GLP-1R stimulation than physiological GLP-1 production — particularly in the brain regions governing appetite. This supratherapeutic receptor activation accounts for the pronounced appetite suppression and weight loss that exceed what dietary or microbiome-based approaches can produce.
Mechanism comparison: GLP-1RA drugs pharmacologically activate GLP-1 receptors. Dietary fiber, gut bacteria, and compounds like berberine work upstream — through different pathways — to support the gut's own GLP-1 production and the metabolic sensitivity that allows GLP-1 signals to function effectively.
What Influences Natural GLP-1 Production
Several diet, lifestyle, and supplement factors have documented effects on endogenous GLP-1 secretion and signaling:
Dietary fiber: Soluble fermentable fiber — including oat beta-glucan, inulin, psyllium, and resistant starch — is the primary dietary driver of SCFA production and, consequently, GLP-1 L-cell stimulation. Multiple randomized controlled trials have shown that increased dietary fiber intake raises post-meal GLP-1 levels.
Protein: High-protein meals are among the strongest dietary stimulators of GLP-1 secretion. The mechanism involves both direct nutrient sensing by L-cells and protein fermentation products.
Berberine: A plant alkaloid found in Berberis plants, berberine activates AMP-activated protein kinase (AMPK) — the same energy-sensing pathway through which dietary restriction improves metabolic function. Multiple clinical trials have demonstrated that berberine improves insulin sensitivity and blood glucose regulation through mechanisms that overlap with GLP-1 signaling, including AMPK activation and gut microbiome modulation toward Akkermansia-enriched populations.
Akkermansia muciniphila: Direct Akkermansia supplementation in humans (Depommier et al., Nature Medicine, 2019) improved multiple metabolic markers including insulin sensitivity and reduced gut permeability — with proposed mechanisms including P9-mediated GLP-1 stimulation.
Exercise: Physical activity acutely increases GLP-1 secretion, and regular exercise has been shown to improve GLP-1 sensitivity — the receptor-level responsiveness to GLP-1 signals — independent of weight loss.
GLP-1 Deficiency: What It Looks Like
There is no clinically defined "GLP-1 deficiency" as a disease entity. However, several patterns of impaired GLP-1 function have been documented:
- People with type 2 diabetes show blunted post-meal GLP-1 secretion compared to people with normal glucose regulation
- Obese individuals show reduced GLP-1 responsiveness to meals
- Gut dysbiosis — reduced microbiome diversity and reduced Akkermansia abundance — correlates with lower SCFA-driven GLP-1 secretion
- Sedentary lifestyle is independently associated with reduced GLP-1 sensitivity
These patterns don't mean everyone benefits equally from GLP-1 support strategies. But they suggest that the gut ecosystem, metabolic health, and lifestyle all intersect at the GLP-1 signaling axis.
Frequently Asked Questions
What does GLP-1 stand for? GLP-1 stands for glucagon-like peptide-1. It's called "glucagon-like" because its amino acid sequence resembles glucagon, a hormone produced by the pancreas.
Is GLP-1 a hormone or a drug? GLP-1 is a naturally occurring hormone produced in the intestine. GLP-1 receptor agonist drugs (semaglutide, liraglutide, tirzepatide) are pharmaceutical compounds that mimic or enhance GLP-1 receptor signaling. They are not GLP-1 itself.
Where is GLP-1 produced? GLP-1 is produced by enteroendocrine L-cells located throughout the small intestine and colon, with higher concentrations in the ileum (lower small intestine) and colon. These cells are directly activated by nutrients and bacterial metabolites.
Does berberine increase GLP-1? Berberine does not directly stimulate GLP-1 secretion the same way that food or fiber does. Rather, berberine activates AMPK, modulates the gut microbiome (increasing Akkermansia abundance), and improves insulin sensitivity through pathways that overlap functionally with GLP-1 signaling.
What foods increase GLP-1? Soluble fiber (oats, legumes, vegetables), high-protein foods, and fermented foods that support gut bacteria are the strongest dietary GLP-1 stimulators. Specific compounds include oat beta-glucan, inulin, and fats that stimulate L-cell fat-sensing receptors.
Can the gut microbiome affect GLP-1 levels? Yes. Gut bacteria produce short-chain fatty acids that directly stimulate L-cell GLP-1 secretion. Akkermansia muciniphila specifically produces a protein (P9) that stimulates GLP-1 via ICAM-2 receptor signaling. Dysbiosis — microbial imbalance — can reduce both SCFA production and Akkermansia-driven GLP-1 stimulation.
How long does it take to naturally increase GLP-1? Dietary changes that increase fiber and support gut bacteria affect GLP-1 acutely (within a meal) and cumulatively (over weeks of microbiome changes). Microbiome remodeling that supports sustained higher GLP-1 production typically takes 4–12 weeks of consistent dietary or probiotic intervention.
Key Takeaways
- GLP-1 is a naturally occurring intestinal hormone that coordinates appetite, blood glucose, and metabolic signaling
- GLP-1 receptor agonist drugs mimic GLP-1 at pharmacological doses — they are not GLP-1 itself
- The gut microbiome is a meaningful determinant of GLP-1 production through SCFA signaling and Akkermansia-specific mechanisms
- Dietary fiber, protein, exercise, and specific gut bacteria all influence natural GLP-1 production
- Supporting the GLP-1 pathway naturally works through fundamentally different mechanisms than pharmaceutical GLP-1RA drugs
Related Reading: - The Gut Foundation: Why Pre-, Pro-, and Postbiotics Are Three Different Things - Akkermansia: The Next-Generation Probiotic Rewriting Gut Health Science - Berberine and AMPK: What the Most-Cited Natural Metabolic Compound Actually Does
This article is for educational purposes and does not constitute medical advice. These statements have not been evaluated by the FDA. Consult your physician before beginning any supplementation program.
References 1. Mojsov S, et al. Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest. 1987. 2. Tolhurst G, et al. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein–coupled receptor FFAR2. Diabetes. 2012. 3. Depommier C, et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nature Medicine. 2019. 4. Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol. 2019. 5. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007. 6. Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018.
